When do the patents on ARGATROBAN IN DEXTROSE expire, and when will generic ARGATROBAN IN DEXTROSE be available?

Sponsor	Phase
Medical University of Vienna	PHASE4
Veralox Therapeutics	Phase 2
Veralox Therapeutics	Phase 1

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sandoz	ARGATROBAN IN DEXTROSE	argatroban	SOLUTION;INTRAVENOUS	201743-001	May 9, 2011		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: October 6, 2026

Argatroban in dextrose is a mature, generic hospital anticoagulant used primarily for heparin-induced thrombocytopenia (HIT) and, in selected cases, percutaneous coronary intervention in patients with HIT. Its commercial profile is defined by low unit volume, high clinical importance, limited branded differentiation, and hospital procurement pressure. Public company filings generally do not report revenue for argatroban in dextrose separately, so product-specific sales and market share cannot be quantified from public disclosures.

The product has no meaningful biologic exclusivity issue, and generic entry risk is high. Commercial performance depends more on manufacturing reliability, sterile injectable capacity, hospital contracts, and shortage conditions than on patent protection.

What is argatroban in dextrose used for?

Argatroban is a direct thrombin inhibitor supplied in a premixed intravenous solution containing argatroban in 5% dextrose. The common premixed presentation is 1 mg/mL in a single-dose intravenous bag. It is used when heparin is contraindicated or must be avoided, especially in patients with suspected or confirmed HIT.

The FDA-approved uses include:

Prophylaxis or treatment of thrombosis in adult patients with HIT.
Anticoagulation during percutaneous coronary intervention in adults with HIT or a high risk of developing HIT.

Argatroban is administered by continuous intravenous infusion and is monitored primarily through activated partial thromboplastin time. The drug is hepatically metabolized, making dose reduction important in patients with hepatic impairment. The FDA labeling recommends a substantially lower starting dose for patients with moderate or severe hepatic dysfunction. (U.S. Food and Drug Administration [FDA], 2023)

Why is the dextrose presentation commercially relevant?

The dextrose presentation is a ready-to-use hospital product. It removes the need to dilute a concentrate before infusion and reduces pharmacy compounding steps. That gives premixed bags a procurement advantage in intensive-care, cardiac, and emergency settings.

The principal commercial limitations are:

Short clinical duration for most patients.
Use concentrated in hospitals and specialty departments.
Competition from bivalirudin and other non-heparin anticoagulants.
Limited ability to raise price in generic hospital tenders.
Dependence on reliable sterile injectable manufacturing.

What is the FDA regulatory status of argatroban in dextrose?

Argatroban was approved in the United States in 2000 for HIT-related anticoagulation. The product is now supplied through generic and institutional channels rather than through a dominant branded franchise.

The regulatory pathway is generally an abbreviated new drug application, or ANDA, for products demonstrating pharmaceutical equivalence and bioequivalence or otherwise meeting the FDA’s applicable requirements for injectable solutions. Premixed argatroban in dextrose products can be approved as sterile injectable solutions with the same active ingredient, strength, route, and therapeutic use as the reference product.

Regulatory attribute	Status
Active ingredient	Argatroban
Dosage form	Intravenous injection or infusion solution
Common premixed strength	1 mg/mL
Diluent	5% dextrose injection
FDA therapeutic category	Direct thrombin inhibitor
Primary use	HIT anticoagulation
Approval origin	U.S. approval in 2000 for argatroban injection
Current market structure	Generic and institutional supply
Biosimilar pathway	Not applicable

FDA labeling identifies argatroban injection as a prescription hospital product. The drug is not a biologic, so the Biologics Price Competition and Innovation Act biosimilar framework does not apply. (FDA, 2023)

What is the Orange Book status of argatroban in dextrose?

Argatroban in dextrose has limited patent-based protection in the current market. The active ingredient and core clinical use are long established, and the product does not have the type of patent estate associated with newer branded drugs.

The FDA Orange Book is the primary public source for approved drug products, therapeutic-equivalence information, and listed patent and exclusivity data. For a mature generic injectable such as argatroban in dextrose, the commercial analysis is driven by the presence or absence of currently listed patents for the specific reference product, not by historical patents that have expired. (FDA, 2024a)

Are there Orange Book patents protecting argatroban in dextrose?

No material unexpired Orange Book patent barrier is generally associated with the mature argatroban injection market. The original active-ingredient and product-protection periods have expired, allowing multiple generic suppliers to compete.

This means:

There is no apparent active-ingredient patent moat.
Method-of-use protection does not prevent generic use for HIT.
Formulation protection is limited for a conventional argatroban-in-dextrose solution.
A new supplier’s principal barriers are FDA approval, sterile manufacturing, validation, and contracting.

The absence of an active patent barrier does not guarantee immediate generic availability. Injectable products can remain supply constrained because FDA approval, manufacturing capacity, quality remediation, and raw-material qualification require time.

When does argatroban in dextrose lose exclusivity?

Argatroban lost meaningful market exclusivity years ago. The original U.S. approval occurred in 2000, and the product now operates in a post-exclusivity generic market.

Exclusivity category	Commercial status
New chemical entity exclusivity	Expired
Orphan-drug exclusivity	Not the principal protection for the product
Pediatric exclusivity	No current commercial significance
Active-ingredient patent	Expired or not commercially blocking
Formulation patent	No broad blocking protection evident
Method-of-use patent	No effective barrier to generic HIT use
Biosimilar exclusivity	Not applicable

Generic entry risk is therefore structural rather than event-driven. No upcoming patent cliff is required to trigger competition because the market has already passed the relevant loss-of-exclusivity point.

How many patents cover argatroban in dextrose?

The practical answer is that no significant unexpired patent portfolio appears to cover the ordinary premixed argatroban-in-dextrose product. Historical patents may have covered argatroban chemistry, synthesis, pharmaceutical compositions, or early clinical applications, but those rights do not create a current barrier to standard generic competition.

A commercial freedom-to-operate review would still need to distinguish:

The active ingredient.
The 5% dextrose vehicle.
The concentration and container system.
Manufacturing and filling processes.
Labeling and method-of-use claims.
Any supplier-specific device or packaging rights.

For the conventional 1 mg/mL premixed bag, the patent risk is low relative to regulatory and manufacturing risk.

What formulations are protected by argatroban patents?

The main marketed formulation is a sterile aqueous argatroban solution in 5% dextrose. It is a conventional formulation rather than a complex delivery system.

Potentially protectable technical attributes could include:

Specific concentration ranges.
Container and closure systems.
pH or stability parameters.
Low-adsorption tubing or bag materials.
Extended-storage conditions.
Manufacturing controls for sterile filling.
Alternative diluents or ready-to-administer presentations.

These attributes may support narrow product or process claims, but they do not appear to create broad market exclusivity for conventional argatroban in dextrose. Hospital customers typically value shelf life, availability, compatibility, and contract price more than formulation differentiation.

Which companies are challenging or competing with argatroban in dextrose?

Competition comes from both direct generic suppliers and alternative anticoagulants.

Direct generic suppliers

The U.S. market has included generic injectable manufacturers and contract suppliers such as Sagent Pharmaceuticals and other hospital-product companies. Product availability can change as manufacturers enter, exit, transfer applications, or experience quality and supply interruptions. FDA labeling and DailyMed listings should be used to confirm the current manufacturer for a specific National Drug Code. (National Library of Medicine, 2024)

The relevant competitive variables are:

Approved presentation and concentration.
Bag size.
NDC availability.
Hospital group-purchasing contracts.
Back-order history.
Manufacturing-site reliability.
Ability to supply during shortages.

Therapeutic competitors

Product	Mechanism	Main competitive position
Argatroban	Direct thrombin inhibitor	Established IV option for HIT, especially where hepatic function is acceptable
Bivalirudin	Direct thrombin inhibitor	Strong alternative in HIT and interventional cardiology
Fondaparinux	Factor Xa inhibitor	Off-label or guideline-supported alternative in selected HIT cases
Danaparoid	Indirect anticoagulant	Used in certain non-U.S. markets; limited U.S. role
Direct oral anticoagulants	Factor Xa or thrombin inhibition	Increasing role in selected patients after stabilization, but not a direct replacement for initial IV management

The American Society of Hematology guidelines identify several non-heparin anticoagulants, including argatroban, bivalirudin, fondaparinux, and direct oral anticoagulants, depending on disease severity, organ function, bleeding risk, and clinical setting. (Cuker et al., 2018)

What generic entry risks exist for argatroban in dextrose?

Generic entry risk is high because the product is an old small-molecule injectable with no meaningful patent barrier. The more relevant risk is additional supplier entry or re-entry, which can reduce contract prices and increase hospital substitution.

Paragraph IV challenges

Paragraph IV litigation is not expected to be a central feature of this market. Paragraph IV certifications are most consequential when an ANDA applicant challenges an unexpired listed patent. With no material blocking patent estate for the conventional product, generic applicants can generally compete through ordinary ANDA pathways rather than relying on a high-value patent challenge.

Potential disputes are more likely to involve:

Product quality.
Labeling differences.
Manufacturing controls.
Trade-secret or process issues.
Contracting and supply allocation.
Patent claims directed to narrow packaging or stability features.

What patent litigation affects argatroban in dextrose?

No major, market-defining patent litigation currently determines U.S. access to conventional argatroban in dextrose. The product’s litigation exposure is low compared with patented specialty drugs.

A litigation event could still arise if a supplier asserted claims covering:

A specific premixed formulation.
A container or closure system.
A stability profile.
A manufacturing process.
A proprietary administration system.

Such claims would likely affect a particular supplier or presentation rather than the entire argatroban market.

How strong is the patent estate for argatroban in dextrose?

The patent estate is weak from an exclusivity perspective and modest from a defensive product-development perspective.

Patent factor	Assessment
Active-ingredient protection	Weak or expired
Core use for HIT	Weak
Conventional dextrose formulation	Weak
Delivery technology	Limited
Manufacturing know-how	Potentially relevant but usually non-public
Orange Book leverage	Low
Litigation leverage	Low
Generic substitution risk	High

The market’s defensibility rests on execution. A supplier with dependable sterile capacity can win share despite having no patent moat. A supplier with patents but unreliable delivery would remain commercially vulnerable.

What is the financial trajectory for argatroban in dextrose?

The financial trajectory is mature, low-growth, and procurement-driven. Public financial reports generally do not isolate argatroban in dextrose revenue from broader injectable portfolios, so product-specific annual sales, gross margin, and market share are not publicly measurable with confidence.

The expected trajectory has four stages:

1. Branded launch and clinical adoption

The initial commercial phase benefited from recognition of argatroban as an alternative to heparin in HIT. Revenue was supported by the lack of broad therapeutic substitutes for patients requiring immediate parenteral anticoagulation.

2. Generic conversion

Generic entry shifted the product from branded pricing to hospital procurement pricing. Unit prices declined, while volume became linked to HIT incidence, hospital admissions, cardiac procedures, and formulary policy.

3. Mature generic competition

The mature phase is characterized by:

Low or moderate unit growth.
Price pressure from tenders and group purchasing organizations.
Periodic supply shortages.
Concentrated demand in hospitals.
Limited promotional spending.
Revenue volatility from contract wins and manufacturing interruptions.

4. Long-term stabilization

Long-term demand is likely to remain clinically durable but commercially limited. The product is unlikely to generate branded-drug growth without a new delivery system, expanded indication, or differentiated supply model.

What factors drive argatroban in dextrose revenue?

The main revenue drivers are clinical volume and supply reliability rather than price expansion.

Demand drivers

Incidence of HIT.
Use of heparin in hospitalized and procedural patients.
Cardiac and vascular procedures.
Intensive-care admissions.
Institutional protocols for non-heparin anticoagulation.
Physician familiarity with argatroban.
Availability of competing direct thrombin inhibitors.

Pricing drivers

Number of approved suppliers.
Group-purchasing organization contracts.
Hospital conversion policies.
Shortage-related allocation.
Bag size and packaging configuration.
Cost of sterile manufacturing.
Distributor inventory.

Margin risks

Low generic prices.
Small manufacturing batches.
Quality investigations.
Raw-material shortages.
Product recalls.
Expensive validation and regulatory remediation.
Excess capacity in sterile injectable manufacturing.

What is the shortage and supply-chain risk for argatroban?

Hospital injectable products have higher supply-chain risk than ordinary oral generics. A single manufacturing interruption can affect the market if only a few suppliers have active inventory.

FDA shortage monitoring is therefore more relevant than patent monitoring for near-term commercial analysis. The key indicators are:

FDA drug-shortage listings.
Manufacturer back-order notices.
Hospital purchasing alerts.
NDC discontinuations.
Changes in DailyMed product listings.
FDA warning letters or manufacturing-site actions.

FDA shortage data should be reviewed separately from patent data because supply risk can emerge without any change in legal exclusivity. (FDA, 2024b)

How does argatroban compare with bivalirudin?

Argatroban and bivalirudin are both direct thrombin inhibitors used in hospital anticoagulation, but they have different commercial and clinical profiles.

Factor	Argatroban in dextrose	Bivalirudin
Primary role	HIT treatment and prevention	HIT, PCI, and procedural anticoagulation
Administration	Continuous IV infusion	IV bolus and/or infusion
Elimination	Predominantly hepatic metabolism	Proteolytic and renal pathways
Hepatic impairment	Dose reduction is important	Different adjustment considerations
Renal impairment	Often commercially attractive relative to renally cleared alternatives	Renal dosing can be important
Patent position	Mature generic market	Product-specific patent and generic status varies
Price profile	Generally generic and procurement-sensitive	Can command different pricing depending on formulation and setting
Main competitive edge	Familiar HIT protocol and hepatic clearance	Procedural use and different pharmacokinetic profile

Argatroban is commercially strongest where hospitals need a readily available, familiar IV HIT therapy and where renal impairment makes alternatives less attractive. Bivalirudin is strongest in procedural settings and institutions with established cardiac or interventional protocols.

What generic launch scenarios are likely?

Base case

Multiple generic suppliers remain active, with low growth and periodic price erosion. Hospitals maintain argatroban on formulary because HIT requires an immediate non-heparin anticoagulant option.

Upside case

A supplier secures a national purchasing contract, benefits from a competitor shortage, or introduces a better-stocked premixed presentation. Revenue rises through volume capture rather than sustained price increases.

Downside case

Bivalirudin gains institutional share, direct oral anticoagulants are used more often after stabilization, or additional generic suppliers compress pricing. A manufacturing interruption can also reduce revenue sharply for an individual supplier.

Severe downside case

A quality action, recall, or prolonged shortage removes a supplier from hospital contracts. The market remains clinically necessary, but the affected company loses share and incurs remediation costs.

What licensing deals affect argatroban in dextrose?

No major publicly disclosed licensing transaction currently defines the market for conventional argatroban in dextrose. Commercial arrangements are more likely to involve:

Contract manufacturing.
Private-label distribution.
Hospital group-purchasing agreements.
Product-portfolio acquisitions.
ANDA transfers.
Regional distribution rights.

These transactions can change supplier economics without changing the underlying patent position. Licensing value is therefore linked to FDA approval, manufacturing capacity, and customer access rather than to exclusivity.

What geographic coverage does argatroban have?

Argatroban is commercially established in the United States and other regulated markets, but product availability varies by country. The United States has a generic hospital market with FDA-approved injectables and institutional purchasing contracts. European and Asian markets may have different branded products, tender structures, clinical guidelines, and reimbursement conditions.

Geographic expansion is constrained by:

Local marketing authorization requirements.
Sterile injectable registration.
National hospital tenders.
Reimbursement rules.
Local pharmacovigilance obligations.
Manufacturing-site acceptance.
Regional treatment practices for HIT.

A company evaluating international expansion should treat each market as a separate injectable procurement opportunity rather than assuming U.S. approval creates automatic global access.

What manufacturing and intellectual-property barriers remain?

Manufacturing is the principal barrier to entry. Argatroban in dextrose is not a complex biologic, but sterile injectable production requires:

Validated aseptic filling.
Container-closure integrity.
Endotoxin and sterility controls.
Stability data.
Qualified active pharmaceutical ingredient.
Extractables and leachables assessment.
Reliable bag and port components.
FDA-compliant quality systems.

The intellectual-property barrier is comparatively low. A new supplier’s investment case depends on the ability to maintain supply, pass FDA inspection, and secure contracts at acceptable margins.

Key Takeaways

Argatroban in dextrose is a mature generic hospital anticoagulant used mainly for HIT.
The common product is a 1 mg/mL premixed solution in 5% dextrose.
Meaningful product exclusivity has expired, and the conventional formulation has limited patent protection.
Paragraph IV litigation is not the central competitive issue because no major blocking patent estate drives market access.
Biosimilar risk does not apply because argatroban is a small-molecule drug.
Revenue is not separately disclosed by most public companies.
Financial performance depends on hospital contracts, generic pricing, supply reliability, and shortages.
Bivalirudin is the principal direct pharmacologic competitor.
Sterile manufacturing and regulatory compliance are stronger barriers than patents.
The market outlook is stable in clinical demand but limited in revenue growth.

FAQs

Is argatroban in dextrose a generic drug?

Yes. Argatroban in dextrose is marketed in a mature generic injectable category, with competition based primarily on FDA approval, supply reliability, packaging, and hospital contracting.

Can a generic manufacturer launch argatroban without challenging a patent?

Generally, yes. The conventional product does not depend on a current, broad patent barrier. An ANDA applicant may proceed through the applicable FDA pathway without a high-value Paragraph IV campaign if no relevant unexpired listed patent blocks approval.

Is argatroban in dextrose interchangeable with bivalirudin?

No. Both are direct thrombin inhibitors, but they have different dosing, elimination, monitoring, labeling, and institutional-use profiles. Substitution requires clinical and formulary review.

Does argatroban have biosimilar competition?

No. Biosimilars apply to biological products. Argatroban is a chemically synthesized small molecule and competes through generic-drug pathways.

What is the main investment risk in argatroban in dextrose?

The main risks are price erosion, limited market size, sterile manufacturing failures, shortages, and loss of hospital contracts. Patent litigation is a secondary risk for the conventional premixed product.

References

Cuker, A., Arepally, G. M., Chong, B. H., Cines, D. B., Greinacher, A., Gruel, Y., Selleng, S., Warkentin, T. E., Wexels, F., Mustafa, R. A., Morgan, R. L., & Santesso, N. (2018). American Society of Hematology 2018 guidelines for management of venous thromboembolism: Heparin-induced thrombocytopenia. Blood Advances, 2(22), 3360-3392. https://doi.org/10.1182/bloodadvances.2018024489

National Library of Medicine. (2024). DailyMed: Argatroban injection products. https://dailymed.nlm.nih.gov/

U.S. Food and Drug Administration. (2023). Argatroban injection prescribing information. https://www.accessdata.fda.gov/

U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

U.S. Food and Drug Administration. (2024b). Drug shortages. https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages>

US Patents:	0
Applicants:	1
NDAs:	1
Clinical Trials:	35
DailyMed Link:	ARGATROBAN IN DEXTROSE at DailyMed

AI Deep Research

Questions you can ask:

Summary for ARGATROBAN IN DEXTROSE

Recent Clinical Trials for ARGATROBAN IN DEXTROSE